Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

CHLORPROMAZINE IN THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS

CHLORPROMAZINE IN THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS The management of anxiety, agitation, and manic states in psychoneurotic and in psychotic patients is a problem inadequately solved by current therapeutic measures. Moreover, conditions such as severe obsessive-compulsive neuroses, chronic hypochondriasis, chronic schizophrenia, and agitated senile states are not consistently amenable either to convulsive or coma therapy or to psychoanalysis and other means of psychotherapy. To control the ever-increasing incidence of psychiatric disturbances, additional therapeutic aids are needed. Recent studies conducted in Europe suggest the usefulness of a new drug, chlorpromazine, for managing and treating psychoneuroses and psychoses. Chemically it is 10-(γ-diethylaminopropyl)-2-chlorophenothiazine hydrochloride. Laboratory investigations1 revealed that this compound possessed diverse pharmacological activity. Provocative from a psychiatric standpoint was its ability to abolish conditioned reflex responses in animals. Chlorpromazine was developed in France and was first studied by French and other European investigators in surgery2 and then in obstetrics3 and psychiatry.4 Observations by Delay, Deniker, http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

CHLORPROMAZINE IN THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS

Winkelman, N. William
JAMA , Volume 155 (1) – May 1, 1954
Download PDF
4 pages

Loading next page...
 
/lp/american-medical-association/chlorpromazine-in-the-treatment-of-neuropsychiatric-disorders-PcR7LZiHhe

References (5)

Publisher
American Medical Association
Copyright
Copyright © 1954 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.1954.03690190024007
Publisher site
See Article on Publisher Site

Abstract

The management of anxiety, agitation, and manic states in psychoneurotic and in psychotic patients is a problem inadequately solved by current therapeutic measures. Moreover, conditions such as severe obsessive-compulsive neuroses, chronic hypochondriasis, chronic schizophrenia, and agitated senile states are not consistently amenable either to convulsive or coma therapy or to psychoanalysis and other means of psychotherapy. To control the ever-increasing incidence of psychiatric disturbances, additional therapeutic aids are needed. Recent studies conducted in Europe suggest the usefulness of a new drug, chlorpromazine, for managing and treating psychoneuroses and psychoses. Chemically it is 10-(γ-diethylaminopropyl)-2-chlorophenothiazine hydrochloride. Laboratory investigations1 revealed that this compound possessed diverse pharmacological activity. Provocative from a psychiatric standpoint was its ability to abolish conditioned reflex responses in animals. Chlorpromazine was developed in France and was first studied by French and other European investigators in surgery2 and then in obstetrics3 and psychiatry.4 Observations by Delay, Deniker,

Journal

JAMA – American Medical Association

Published: May 1, 1954

There are no references for this article.